PE Anti-Human TNFRSF9/CD137 Rabbit Recombinant Antibody

TNFRSF9/CD137 Uni-rAbTM Recombinant Antibody for FC
Cat No. PE-98112

产品说明书

CloneNo. 241344F3

宿主/亚型

Rabbit / IgG

种属反应性

human

应用

FC

TNFRSF9, ILA, CD137, 4-1BB ligand receptor, 4 1BB ligand receptor

缓冲液配方:  PBS and Azide
PBS and Azide
偶联物:  PE
规格: 

-/ -


经过测试的应用

Positive FC detected inCon-A treated human PBMCs

推荐稀释比

应用推荐稀释比
This reagent has been pre-titrated and tested for flow cytometric analysis. The suggested use of this reagent is 5 ul per 10^6 cells in a 100 µl suspension or 5 ul per 100 µl of whole blood.
Sample-dependent, Check data in validation data gallery.

产品信息

PE-98112 targets TNFRSF9/CD137 in FC applications and shows reactivity with human samples.

经测试应用 FC Application Description
经测试反应性 human
免疫原 Recombinant Protein 种属同源性预测
宿主/亚型 Rabbit / IgG
抗体类别 Recombinant
产品类型 Antibody
全称 tumor necrosis factor receptor superfamily, member 9
别名 TNFRSF9, ILA, CD137, 4-1BB ligand receptor, 4 1BB ligand receptor
计算分子量 28 kDa
GenBank蛋白编号BC006196
基因名称 TNFRSF9/CD137
Gene ID (NCBI) 3604
偶联类型 PE Fluorescent Dye
最大激发/发射波长496 nm, 565 nm / 578 nm
形式 Liquid
纯化方式Protein A purification
UNIPROT IDQ07011
储存缓冲液 PBS with 0.09% sodium azide and 0.5% BSA , pH 7.3
储存条件Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment.

背景介绍

CD137, also known as TNFRSF9 or 4-1BB, is an inducible T cell surface receptor that belongs to the tumor necrosis factor receptor superfamily. CD137 is a transmembrane protein expressed on the surface of activated T-cells. In addition, activation-dependent expression of CD137 has also been found in B lymphocytes, monocytes, and diverse nonlymphoid cell types. CD137 provides a co-stimulatory signal that enhances the survival, and differentiation of cells, and has a crucial role in the development of CD8 cytotoxic T cells and anti-tumor immunity. (PMID: 9826581; 23696891)

实验方案

Product Specific Protocols
FC protocol for PE TNFRSF9/CD137 antibody PE-98112Download protocol
Standard Protocols
Click here to view our Standard Protocols
Loading...